Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Forte Biosciences, Inc. (FBRX) had Return on Tangible Equity of -40.64% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-24.79M |
|
-- |
|
-- |
|
$24.57M |
|
$-24.57M |
|
$0.82M |
|
$-23.75M |
|
$-23.75M |
|
$-24.79M |
|
$-24.79M |
|
$-24.79M |
|
$-24.79M |
|
$-24.57M |
|
$-24.54M |
|
14.72M |
|
14.72M |
|
$-1.39 |
|
$-1.39 |
|
| Balance Sheet Financials | |
$80.59M |
|
$0.13M |
|
$2.19M |
|
$82.78M |
|
$20.75M |
|
-- |
|
$1.04M |
|
$21.79M |
|
$60.99M |
|
$60.99M |
|
$60.99M |
|
12.95M |
|
| Cash Flow Statement Financials | |
$-50.88M |
|
$36.23M |
|
$69.36M |
|
$22.24M |
|
$76.96M |
|
$54.71M |
|
$6.26M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.88 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-51.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-40.64% |
|
|
Return on Tangible Equity |
-40.64% |
-29.94% |
|
-40.64% |
|
$4.71 |
|
$-3.47 |
|
$-3.46 |
|